Skip to main content
ROIV logo

Roivant Sciences Ltd. (ROIV) Stock: Price, Forecast & Analyst Target

Roivant Sciences Ltd. (ROIV) — MoonshotScore 27/100 (Weak band), calculated Nov 18, 2026. Price $38.96 (+0.59%), as of the Nov 19, 2026 trading session; market cap $28.2B.

Educational signal · not a buy or sell recommendation · How to read this

$38.96 +$0.23 (+0.59%) Market Cap $28.2B

Roivant Sciences Ltd. · ROIV · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-12: Roivant Sciences is a drug developer spanning oncology, hematology, immunology, dermatology, rare disease and infectious disease, not a mature biotechnology company whose reported revenue tracks medicine demand. Its case rests on whether that broad pipeline can create valuable therapies before sustained research spending consumes too much of its financial cushion.

Price as of Nov 19, 2026

Key Statistics

27 of 100

MoonshotScore v2 · Roivant Sciences (ROIV)

Weak
Business Quality Thin (26)
Financial Safety Sound (72)
Valuation Full (44)
Growth Durability Growing (73)
Momentum Surging (93)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A strong balance sheet and durable growth, but weak quality and a full valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Sound; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • quarterly revenue $2M (Q2 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 44.15 · Piotroski F 2

Holding back: weak fundamentals

Helping: balance-sheet strength, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ROIV (52 recorded, newest six shown)
RecordedScoreBand
31Weak
31Weak
26Weak
26Weak
27Weak
27Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$38.96
Change on the day+0.59%
52-week range$19.96–$42.50
Market capitalisation$28.2B—
Price / earnings (trailing)-21.81
Shares traded on the day4.93M
Beta (volatility vs the S&P 500)1.2

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $17, high $41, latest $39. $41 $17 high $41 Oct 17, 2025 Nov 19, 2026 · $39 $17Oct 17, 2025$20Oct 31, 2025$20Nov 14, 2025$21Nov 28, 2025$22Dec 12, 2025$22Dec 26, 2025$22Jan 9, 2026$23Jan 23, 2026$26Feb 6, 2026$27Feb 20, 2026$29Mar 6, 2026$28Mar 20, 2026$28Apr 2, 2026$30Apr 17, 2026$28May 1, 2026$29May 15, 2026$30May 29, 2026$30Jun 12, 2026$34Jun 26, 2026$36Jul 10, 2026$35Jul 24, 2026$36Aug 7, 2026$36Aug 21, 2026$35Sep 4, 2026$40Sep 18, 2026$36Oct 2, 2026$34Oct 16, 2026$37Oct 30, 2026$40Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Roivant Sciences (ROIV): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Weak
Financial Safety Moderate
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Three of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Roivant Sciences (ROIV), and what does it report?

Short answer · as of

Roivant discovers and advances therapeutic candidates across a wide disease range.

The income statement currently measures a development organization: revenue is reported through a consolidated segment and remains minor beside research and administrative expense, so sales trends reveal little about the pipeline’s economic potential.

Reported net income can also diverge sharply from operating performance. Profitable periods have appeared despite deep operating losses, making research expense, operating loss and cash use more informative measures of the underlying business than headline earnings alone.

2 · Latest results

What do the latest results show for Roivant Sciences (ROIV)?

Short answer · as of

The most recent reported quarter, Q2 FY2025, carried revenue of $2M.

The latest period showed lower revenue, higher research spending, a wider operating loss and heavier operating cash use. Net income also swung back to a loss after the preceding period’s profit, while revenue again fell short of the prevailing estimate.

The mechanism is straightforward: Roivant is funding drug development at a scale far beyond its current revenue base. Rising research expense therefore widens the operating deficit unless program economics, licensing income or eventual medicine sales begin contributing enough to absorb that spending.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2025$2M-$114M-$0.17 (diluted)
Q3 FY2025$2M-$266M-$0.38 (diluted)
Q4 FY2025$3M$303M$0.37 (diluted)
Q1 FY2026$1M-$190M-$0.26 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Roivant Sciences (ROIV)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Cash and investments substantially exceed debt and liabilities, giving Roivant meaningful capacity to keep funding development. Liquidity ratios and low financial leverage reinforce that strength, but operating cash flow has remained negative throughout the reported series and the cash balance has declined materially.

That cushion does not remove pipeline risk. A clinical setback, delay or abandoned program can destroy expected value while research and administrative costs continue, and the market value already stands far above net cash; the valuation therefore depends chiefly on therapeutic outcomes rather than balance-sheet assets.

Data-derived red flags

  • Negative return on equity (-8.5%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Roivant Sciences (ROIV)?

Short answer · as of

Analyst estimates on file carry FY2027 revenue $157.85M · EPS -1.15 · 7 analysts.

Research spending, operating loss and operating cash use should be read together. Stabilizing cash consumption while programs advance would preserve strategic room; another acceleration in burn without a corresponding improvement in pipeline economics would make the cash reserve less protective.

Reported revenue should be judged against its limited role rather than treated as a conventional sales-growth signal. The useful near-term checks are whether revenue continues missing expectations, whether the loss profile worsens, and whether the cash balance keeps falling at the recent pace.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • The newest quarter held here (Q2 FY2025) was filed Nov 10, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Roivant Sciences compare with its peers?

Short answer

Roivant Sciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a biotechnology company built around an established commercial franchise, Roivant offers broader therapeutic exposure but far less support from current product economics. Its defining combination is a wide development pipeline, negligible reported revenue, heavy research spending and unusually strong liquidity relative to debt.

Compared with a narrowly financed development-stage peer, Roivant can sustain more setbacks before financing pressure dominates. The tradeoff is that its market value exceeds its net cash by a wide margin, while long-range revenue estimates span a broad range; investors are paying mainly for uncertain pipeline value rather than present earnings power.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Named competitor$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Royalty Pharma plc (RPRX) Named competitor$68.67 Nov 18, 2026$39.5B73 5-pillar Nov 18, 2026
Genmab A/S (GMAB) Same industry, near in market value$50.97 Nov 18, 2026$31.4B72 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Roivant Sciences (ROIV) — this page$38.96$28.2B27

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$41.00 – $62.00
Consensus target
$49.50
Median target
$49.00
Revenue estimate
$157.85M
EPS estimate
$-1.15

Consensus record · Captured .

Measured against a quoted price of $38.96 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
100
Identified insiders
12
Purchases
0
Sales
26
Other transactions
74

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ROIV in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Viking GlobalAndreas HalvorsenQ3 20260.76%$247.12MAdded +7.7% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Roivant Sciences (ROIV)?

Read these with our analysis →

Common Questions About ROIV (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why does Roivant’s oncology-to-immunology pipeline produce so little reported revenue?

Roivant is primarily advancing therapeutic candidates rather than harvesting a mature commercial portfolio. Its reported revenue is therefore small beside research spending and does not capture the potential value of programs still under development.

Why can Roivant’s net result turn positive while its operating result remains deeply negative?

The divergence indicates that items outside core operations can dominate the headline result. Persistent operating losses show that the development organization itself remains costly regardless of occasional reported profits.

Can Roivant’s thin reported revenue fund its broad drug-development program?

Current revenue covers only a small portion of research and administrative spending, leaving cash reserves to finance the gap. Continued negative operating cash flow confirms that the program is not self-funding.

What would make Roivant’s large cash reserve less reassuring as research spending rises?

Persistent cash consumption without stronger program economics would steadily reduce the protection that liquidity provides. The warning pattern would be rising research expense, widening operating losses and continued erosion of cash and short-term investments.

What is the ROIV stock price today?

The last price recorded for Roivant Sciences Ltd. (ROIV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ROIV price target?

The analyst consensus price target for Roivant Sciences Ltd. (ROIV), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 28 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Sector / industry (provider taxonomy); Business description; Annual revenue and net result (USD millions); Cash, investments and debt; Cash decline over the reported window
  • 1. What is Roivant Sciences (ROIV), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • 2. What do the latest results show for Roivant Sciences (ROIV)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Annual revenue and net result (USD millions); Revenue by segment
  • 3. What are the financial strengths and risks for Roivant Sciences (ROIV)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Cash against market value; Business description
  • 4. What should you watch next at Roivant Sciences (ROIV)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Reported versus estimated, last 8 quarters; Next earnings report; Analyst revenue and earnings estimates (average)
  • 5. How does Roivant Sciences compare with its peers?: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Cash, investments and debt; Trailing twelve-month ratio set; Cash against market value; Analyst revenue and earnings estimates (average)
  • FAQ: Why does Roivant’s oncology-to-immunology pipeline produce so little reported revenue?: Business description; Annual revenue and net result (USD millions); Revenue by segment; Quarterly income statement (USD thousands)
  • FAQ: Why can Roivant’s net result turn positive while its operating result remains deeply negative?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: Can Roivant’s thin reported revenue fund its broad drug-development program?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt
  • FAQ: What would make Roivant’s large cash reserve less reassuring as research spending rises?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash and investment components
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ROIV

Funds in our ETF coverage that list ROIV among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
State Street SPDR S&P Biotech ETF (XBI)1.74%